Related Experiment Video

Updated: Jan 25, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K

New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise

Stephan R Bohl1, Lars Bullinger2, Frank G Rücker3

  • 1Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany. stephanrm.bohl@gmail.com.

International Journal of Molecular Sciences
|April 26, 2019
PubMed

Insights

Recent advances in understanding acute myeloid leukemia (AML) molecular complexity have led to new targeted therapies. These novel agents, approved by the FDA, show improved patient outcomes when combined with conventional AML treatments.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Standard cytotoxic treatments for acute myeloid leukemia (AML) have seen limited progress over the past four decades.
  • Recent breakthroughs in understanding AML's molecular heterogeneity have identified new therapeutic targets.

Purpose of the Study:

  • To review newly approved and emerging targeted agents for AML treatment.
  • To discuss the clinical benefits, limitations, and controversial aspects of targeted AML therapies.

Main Methods:

  • Literature review of recent advancements in AML targeted therapy.
  • Analysis of FDA-approved targeted agents and their clinical applications.
  • Discussion of combination strategies with conventional AML treatments.

Main Results:

  • Seven new targeted agents have received FDA approval for AML treatment in the last two years.
  • These agents demonstrate clinical benefit as single agents and improved outcomes when combined with conventional therapy.
  • Ongoing research focuses on promising upcoming agents and refining targeted treatment strategies.

Conclusions:

  • Targeted therapies represent a significant advancement in AML treatment, improving patient outcomes.
  • Combination strategies of targeted agents with conventional therapy are particularly effective.
  • Further research is needed to address limitations and controversial aspects of targeted AML treatment.
Keywords:
AMLBCL2FLT3IDH1/2hedgehogimmunogenic treatmenttargeted therapy

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.8K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.7K

Related Concept Videos

Rise of Liquid in a Capillary Tube01:18

Rise of Liquid in a Capillary Tube

When very thin cylindrical tubes, called capillaries, are dipped in a liquid, the liquid rises or falls in the tube compared to the surrounding liquid. This phenomenon is called capillary action. Capillary action occurs due to the combination of two opposing forces: the cohesive forces of the liquid, which cause it to stick to itself and form a rounded shape, and the adhesive forces between the liquid and the walls of the container, which cause the liquid to be attracted to the container walls.
3.2K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
550
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.0K
Air-entraining Agents01:27

Air-entraining Agents

Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
264
Masking and Demasking Agents01:19

Masking and Demasking Agents

EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
618